Mitani Hironobu, Takimoto Misato, Kimura Masaaki
Research Division, Tsukuba Research Institute, Novartis Pharma K.K., Japan.
Jpn J Pharmacol. 2002 Apr;88(4):451-8. doi: 10.1254/jjp.88.451.
The aim of this study was to investigate the effects of aging on glucose metabolism after oral glucose challenge in aged dipeptidyl peptidase IV (DPP-IV) positive (+) Fischer 344 (F344), DPP-IV deficient (-) F344 and DPP-IV(+) Wistar rats and to determine the effect of a DPP-IV inhibitor NVP-DPP728 (1-[2-[(5-cyanopyridin-2-yl)amino]ethylamino]acetyl-2-cyano-(S)-pyrrolidine monohydrochloride salt) on glucose tolerance in aged rats. Aging caused a decrease in early insulin response after an oral glucose challenge in aged Wistar or DPP-IV(+) F344 rats, but not in aged DPP-IV(-) F344 rats, compared with young control groups. Glucose tolerance after an oral glucose challenge in aged DPP-IV(-) F344 rats was better than in aged DPP-IV(+) F344 and Wistar rats associated with the preservation of the early insulin response. NVP-DPP728 improved the glucose tolerance after an oral glucose challenge by potentiating the early insulin response throughout the inhibition of plasma DPP-IV activity in aged DPP-IV(+) Wistar and F344 rats. In contrast, NVP-DPP728 did not affect the glucose tolerance after an oral glucose challenge in aged DPP-IV(-) F344 rats. These results indicate that treatment with NVP-DPP728 ameliorated glucose tolerance in aged rats by the direct inhibition of plasma DPP-IV activity and presumably the subsequent increase in endogenous incretin action.
本研究旨在探讨衰老对老年二肽基肽酶IV(DPP-IV)阳性(+)的Fischer 344(F344)大鼠、DPP-IV缺陷(-)的F344大鼠以及DPP-IV(+)的Wistar大鼠口服葡萄糖激发后葡萄糖代谢的影响,并确定DPP-IV抑制剂NVP-DPP728(1-[2-[(5-氰基吡啶-2-基)氨基]乙基氨基]乙酰基-2-氰基-(S)-吡咯烷盐酸盐)对老年大鼠葡萄糖耐量的影响。与年轻对照组相比,衰老导致老年Wistar或DPP-IV(+)F344大鼠口服葡萄糖激发后早期胰岛素反应降低,但老年DPP-IV(-)F344大鼠未出现这种情况。老年DPP-IV(-)F344大鼠口服葡萄糖激发后的葡萄糖耐量优于老年DPP-IV(+)F344大鼠和Wistar大鼠,这与早期胰岛素反应的保留有关。NVP-DPP728通过增强老年DPP-IV(+)Wistar和F344大鼠血浆DPP-IV活性的抑制作用来增强早期胰岛素反应,从而改善口服葡萄糖激发后的葡萄糖耐量。相比之下,NVP-DPP728对老年DPP-IV(-)F344大鼠口服葡萄糖激发后的葡萄糖耐量没有影响。这些结果表明,NVP-DPP728治疗通过直接抑制血浆DPP-IV活性以及可能随后增加内源性肠促胰岛素作用,改善了老年大鼠的葡萄糖耐量。